ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:PRQR
- CUSIP: N/A
- Web: www.proqr-tx.com
- Market Cap: $119.33 million
- Outstanding Shares: 23,865,000
- 50 Day Moving Avg: $4.97
- 200 Day Moving Avg: $4.58
- 52 Week Range: $3.65 - $8.70
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.49
- P/E Growth: 0.00
- Annual Revenue: $1.46 million
- Price / Sales: 81.73
- Book Value: $2.09 per share
- Price / Book: 2.39
- EBIDTA: ($43,170,000.00)
- Return on Equity: -48.21%
- Return on Assets: -41.85%
- Debt-to-Equity Ratio: 0.06%
- Current Ratio: 8.90%
- Quick Ratio: 8.90%
- Average Volume: 60,203 shs.
- Beta: 0.87
- Short Ratio: 1.44
Frequently Asked Questions for ProQR Therapeutics NV (NASDAQ:PRQR)
What is ProQR Therapeutics NV's stock symbol?
ProQR Therapeutics NV trades on the NASDAQ under the ticker symbol "PRQR."
How were ProQR Therapeutics NV's earnings last quarter?
ProQR Therapeutics NV (NASDAQ:PRQR) posted its earnings results on Wednesday, May, 17th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. View ProQR Therapeutics NV's Earnings History.
Where is ProQR Therapeutics NV's stock going? Where will ProQR Therapeutics NV's stock price be in 2017?
5 equities research analysts have issued twelve-month price objectives for ProQR Therapeutics NV's shares. Their forecasts range from $4.50 to $40.00. On average, they expect ProQR Therapeutics NV's share price to reach $16.38 in the next year. View Analyst Ratings for ProQR Therapeutics NV.
Are investors shorting ProQR Therapeutics NV?
ProQR Therapeutics NV saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 132,463 shares, an increase of 2.2% from the April 13th total of 129,576 shares. Based on an average daily volume of 12,916 shares, the short-interest ratio is presently 10.3 days.
Who are some of ProQR Therapeutics NV's key competitors?
Some companies that are related to ProQR Therapeutics NV include Abeona Therapeutics (ABEO), Cerus (CERS), Aratana Therapeutics (PETX), Chimerix (CMRX), Codexis (CDXS), Cascadian Therapeutics (CASC), Osiris Therapeutics (OSIR), Cempra (CEMP), Arbutus Biopharma Corp (ABUS), Madrigal Pharmaceuticals (MDGL), Fortress Biotech (FBIO), Stemline Therapeutics (STML), Immune Design Corp (IMDZ), Corium International (CORI), Enzymotec Ltd (ENZY), Pieris Pharmaceuticals (PIRS), RedHill Biopharma Ltd - (RDHL) and Novelion Therapeutics (NVLN).
Who owns ProQR Therapeutics NV stock?
ProQR Therapeutics NV's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (11.07%), Redmile Group LLC (6.65%), Janus Capital Management LLC (1.64%), Sphera Funds Management LTD. (1.41%), FMR LLC (1.02%) and Principal Financial Group Inc. (0.33%). View Institutional Ownership Trends for ProQR Therapeutics NV.
Who sold ProQR Therapeutics NV stock? Who is selling ProQR Therapeutics NV stock?
Who bought ProQR Therapeutics NV stock? Who is buying ProQR Therapeutics NV stock?
How do I buy ProQR Therapeutics NV stock?
Shares of ProQR Therapeutics NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ProQR Therapeutics NV stock cost?
One share of ProQR Therapeutics NV stock can currently be purchased for approximately $5.00.
Earnings History for ProQR Therapeutics NV (NASDAQ:PRQR)Earnings History by Quarter for ProQR Therapeutics NV (NASDAQ:PRQR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for ProQR Therapeutics NV (NASDAQ:PRQR)
2017 EPS Consensus Estimate: ($2.10)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for ProQR Therapeutics NV (NASDAQ:PRQR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ProQR Therapeutics NV (NASDAQ:PRQR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ProQR Therapeutics NV (NASDAQ:PRQR)
Latest Headlines for ProQR Therapeutics NV (NASDAQ:PRQR)
ProQR Therapeutics NV (PRQR) Chart for Wednesday, May, 24, 2017